@enoughhealth: A single randomized, double-blind trial out of UC San Diego — published in npj Aging, July 2026 — found semaglutide slowed biological aging by 9% on the DunedinPACE epigenetic clock over 32 weeks. That's a cellular aging measure, not a weight metric. One trial. Early-stage signal. Science is intriguing, not settled — and GLP-1s remain an active area of longevity research, not an established longevity treatment. For adults 18+: talk to a licensed clinician before making any health decision. This is not medical advice. Source: UC San Diego / npj Aging, July 2026. Health. Simplified. #GLP1 #LongevityScience #BiologicalAge #HealthOptimization #EnoughHealth #Semaglutide

enoughhealth

Open In TikTok:

Region: US

Wednesday 19 August 2026 20:30:19 GMT